Europe – Pre-authorisation guidance

These questions and answers (Q&As) provide an overview of the European Medicines Agency’s (EMA) advice on issues that are typically addressed in discussions or meetings with marketing authorisation holders in the application phase.

This guidance should be read in conjunction with the rules governing medicinal products in the European Union, volume 2, notice to applicants and pre-submission guidance documents…